Table of Contents

2019-2024 Global Liraglutide Consumption Market Report

1 Scope of the Report

• 1.1 Market Introduction
• 1.2 Research Objectives
• 1.3 Years Considered
• 1.4 Market Research Methodology
• 1.5 Economic Indicators
• 1.6 Currency Considered

2 Executive Summary

• 2.1 World Market Overview
  • 2.1.1 Global Liraglutide Consumption 2014-2024
  • 2.1.2 Liraglutide Consumption CAGR by Region
• 2.2 Liraglutide Segment by Type
  • 2.2.1 Pills
  • 2.2.2 Liquid
• 2.3 Liraglutide Consumption by Type
  • 2.3.1 Global Liraglutide Consumption Market Share by Type (2014-2019)
  • 2.3.2 Global Liraglutide Revenue and Market Share by Type (2014-2019)
  • 2.3.3 Global Liraglutide Sale Price by Type (2014-2019)
• 2.4 Liraglutide Segment by Application
  • 2.4.1 Hospital
  • 2.4.2 Drug Store
• 2.5 Liraglutide Consumption by Application
  • 2.5.1 Global Liraglutide Consumption Market Share by Application (2014-2019)
  • 2.5.2 Global Liraglutide Value and Market Share by Application (2014-2019)
  • 2.5.3 Global Liraglutide Sale Price by Application (2014-2019)

3 Global Liraglutide by Players

• 3.1 Global Liraglutide Sales Market Share by Players
  • 3.1.1 Global Liraglutide Sales by Players (2017-2019)
  • 3.1.2 Global Liraglutide Sales Market Share by Players (2017-2019)
• 3.2 Global Liraglutide Revenue Market Share by Players
  • 3.2.1 Global Liraglutide Revenue by Players (2017-2019)
  • 3.2.2 Global Liraglutide Revenue Market Share by Players (2017-2019)
• 3.3 Global Liraglutide Sale Price by Players
• 3.4 Global Liraglutide Manufacturing Base Distribution, Sales Area, Product Types by Players
  • 3.4.1 Global Liraglutide Manufacturing Base Distribution and Sales Area by Players
  • 3.4.2 Players Liraglutide Products Offered
• 3.5 Market Concentration Rate Analysis
  • 3.5.1 Competition Landscape Analysis
  • 3.5.2 Concentration Ratio (CR3, CR5 and CR10) (2017-2019)
• 3.6 New Products and Potential Entrants
• 3.7 Mergers & Acquisitions, Expansion

4 Liraglutide by Regions

• 4.1 Liraglutide by Regions
  • 4.1.1 Global Liraglutide Consumption by Regions
  • 4.1.2 Global Liraglutide Value by Regions
• 4.2 Americas Liraglutide Consumption Growth
• 4.3 APAC Liraglutide Consumption Growth
• 4.4 Europe Liraglutide Consumption Growth
• 4.5 Middle East & Africa Liraglutide Consumption Growth

5 Americas

• 5.1 Americas Liraglutide Consumption by Countries
  • 5.1.1 Americas Liraglutide Consumption by Countries (2014-2019)
  • 5.1.2 Americas Liraglutide Value by Countries (2014-2019)
• 5.2 Americas Liraglutide Consumption by Type
• 5.3 Americas Liraglutide Consumption by Application
• 5.4 United States
• 5.5 Canada
• 5.6 Mexico
• 5.7 Key Economic Indicators of Few Americas Countries

6 APAC

• 6.1 APAC Liraglutide Consumption by Countries
  • 6.1.1 APAC Liraglutide Consumption by Countries (2014-2019)
  • 6.1.2 APAC Liraglutide Value by Countries (2014-2019)
• 6.2 APAC Liraglutide Consumption by Type
• 6.3 APAC Liraglutide Consumption by Application
• 6.4 China
• 6.5 Japan
• 6.6 Korea
• 6.7 Southeast Asia
• 6.8 India
• 6.9 Australia
• 6.10 Key Economic Indicators of Few APAC Countries

7 Europe

• 7.1 Europe Liraglutide by Countries
  • 7.1.1 Europe Liraglutide Consumption by Countries (2014-2019)
  • 7.1.2 Europe Liraglutide Value by Countries (2014-2019)
• 7.2 Europe Liraglutide Consumption by Type
• 7.3 Europe Liraglutide Consumption by Application
• 7.4 Germany
• 7.5 France
• 7.6 UK
• 7.7 Italy
• 7.8 Russia
• 7.9 Spain
• 7.10 Key Economic Indicators of Few Europe Countries

8 Middle East & Africa

• 8.1 Middle East & Africa Liraglutide by Countries
  • 8.1.1 Middle East & Africa Liraglutide Consumption by Countries (2014-2019)
  • 8.1.2 Middle East & Africa Liraglutide Value by Countries (2014-2019)
• 8.2 Middle East & Africa Liraglutide Consumption by Type
• 8.3 Middle East & Africa Liraglutide Consumption by Application
• 8.4 Egypt
• 8.5 South Africa
• 8.6 Israel
• 8.7 Turkey
• 8.8 GCC Countries

9 Market Drivers, Challenges and Trends

• 9.1 Market Drivers and Impact
  • 9.1.1 Growing Demand from Key Regions
  • 9.1.2 Growing Demand from Key Applications and Potential Industries
• 9.2 Market Challenges and Impact
• 9.3 Market Trends

10 Marketing, Distributors and Customer

• 10.1 Sales Channel
  • 10.1.1 Direct Channels
  • 10.1.2 Indirect Channels
• 10.2 Liraglutide Distributors
• 10.3 Liraglutide Customer

11 Global Liraglutide Market Forecast

• 11.1 Global Liraglutide Consumption Forecast (2019-2024)
• 11.2 Global Liraglutide Forecast by Regions
  • 11.2.1 Global Liraglutide Forecast by Regions (2019-2024)
  • 11.2.2 Global Liraglutide Value Forecast by Regions (2019-2024)
  • 11.2.3 Americas Consumption Forecast
  • 11.2.4 APAC Consumption Forecast
  • 11.2.5 Europe Consumption Forecast
  • 11.2.6 Middle East & Africa Consumption Forecast
• 11.3 Americas Forecast by Countries
  • 11.3.1 United States Market Forecast
  • 11.3.2 Canada Market Forecast
  • 11.3.3 Mexico Market Forecast
  • 11.3.4 Brazil Market Forecast
• 11.4 APAC Forecast by Countries
  • 11.4.1 China Market Forecast
  • 11.4.2 Japan Market Forecast
  • 11.4.3 Korea Market Forecast
  • 11.4.4 Southeast Asia Market Forecast
  • 11.4.5 India Market Forecast
  • 11.4.6 Australia Market Forecast
• 11.5 Europe Forecast by Countries
  • 11.5.1 Germany Market Forecast
  • 11.5.2 France Market Forecast
  • 11.5.3 UK Market Forecast
  • 11.5.4 Italy Market Forecast
  • 11.5.5 Russia Market Forecast
  • 11.5.6 Spain Market Forecast
• 11.6 Middle East & Africa Forecast by Countries
  • 11.6.1 Egypt Market Forecast
  • 11.6.2 South Africa Market Forecast
  • 11.6.3 Israel Market Forecast
  • 11.6.4 Turkey Market Forecast
  • 11.6.5 GCC Countries Market Forecast
• 11.7 Global Liraglutide Forecast by Type
• 11.8 Global Liraglutide Forecast by Application

12 Key Players Analysis

• 12.1 HEC Pharm
  • 12.1.1 Company Details
  • 12.1.2 Liraglutide Product Offered
  • 12.1.3 HEC Pharm Liraglutide Sales, Revenue, Price and Gross Margin (2017-2019)
  • 12.1.4 Main Business Overview
  • 12.1.5 HEC Pharm News
• 12.2 Bachem
  • 12.2.1 Company Details
  • 12.2.2 Liraglutide Product Offered
  • 12.2.3 Bachem Liraglutide Sales, Revenue, Price and Gross Margin (2017-2019)
  • 12.2.4 Main Business Overview
  • 12.2.5 Bachem News
• 12.3 Bharat Pharmaceuticals
  • 12.3.1 Company Details
  • 12.3.2 Liraglutide Product Offered
  • 12.3.3 Bharat Pharmaceuticals Liraglutide Sales, Revenue, Price and Gross Margin (2017-2019)
  • 12.3.4 Main Business Overview
  • 12.3.5 Bharat Pharmaceuticals News
• 12.4 Kingpep Biotechnology
  • 12.4.1 Company Details
  • 12.4.2 Liraglutide Product Offered
  • 12.4.3 Kingpep Biotechnology Liraglutide Sales, Revenue, Price and Gross Margin (2017-2019)
  • 12.4.4 Main Business Overview
  • 12.4.5 Kingpep Biotechnology News
• 12.5 Shenzhen JYMed Technology
  • 12.5.1 Company Details
  • 12.5.2 Liraglutide Product Offered
  • 12.5.3 Shenzhen JYMed Technology Liraglutide Sales, Revenue, Price and Gross Margin (2017-2019)
  • 12.5.4 Main Business Overview
  • 12.5.5 Shenzhen JYMed Technology News
• 12.6 Wuxi Asiapeptide
  • 12.6.1 Company Details
  • 12.6.2 Liraglutide Product Offered
  • 12.6.3 Wuxi Asiapeptide Liraglutide Sales, Revenue, Price and Gross Margin (2017-2019)
  • 12.6.4 Main Business Overview
  • 12.6.5 Wuxi Asiapeptide News
• 12.7 AmbioPharm
  • 12.7.1 Company Details
  • 12.7.2 Liraglutide Product Offered
  • 12.7.3 AmbioPharm Liraglutide Sales, Revenue, Price and Gross Margin (2017-2019)
  • 12.7.4 Main Business Overview
  • 12.7.5 AmbioPharm News

...

13 Research Findings and Conclusion

Liraglutide (NN2211) is a long-acting glucagon-like peptide-1 receptor agonist, binding to the same receptors as does the endogenous metabolic hormone GLP-1 that stimulates insulin secretion. Marketed under the brand name Victoza, it is an injectable drug developed by Novo Nordisk for the treatment of type 2 diabetes. In 2015, Novo Nordisk began marketing it in the U.S. under the brand name Saxenda as a treatment for obesity in adults with at least one weight-related comorbid condition.
The total amount of Patents about Liraglutide are 1871, among those Patents, 44%is about application, 26%is about Combination therapy, and 12%is about Preparation method.
In these patents, accounting for Europe is the largest, followed by North America, and finally Asia.
The application of Liraglutide
Liraglutide for the treatment of type 2 diabetes mellitus
Liraglutide 1.2 mg daily in triple therapy regimens (in combination with metformin and a sulphonylurea, or metformin and a thiazolidinedione) is recommended as an option for the treatment of people with type 2 diabetes, only if used as described for exenatide in 'Type 2 diabetes: the management of type 2 diabetes'
Liraglutide 1.2 mg daily in dual therapy regimens (in combination with metformin or a sulphonylurea) is recommended as an option for the treatment of people with type 2 diabetes, only if the person is intolerant of either metformin or a sulphonylurea, or treatment with metformin or a sulphonylurea is contraindicated, and the person is intolerant of thiazolidinediones and dipeptidyl peptidase-4 (DPP-4) inhibitors, or treatment with thiazolidinediones and DPP-4 inhibitors is contraindicated.
Liraglutide 1.8 mg daily is not recommended for the treatment of people with type 2 diabetes.
The Committee concluded that the evidence provided was not robust enough to allow it to recommend liraglutide as a cost-effective alternative to either thiazolidinediones or DPP-4 inhibitors as a triple therapy regimen, however it believes liraglutide is a cost-effective treatment option relative to exenatide.

Taking into account the lack of clinical trial evidence showing a significant benefit from increasing the liraglutide dose from 1.2 mg to 1.8 mg, the widely varying ICERs and the uncertainty in the economic analysis, the Committee was unable to recommend liraglutide 1.8 mg for the treatment of type 2 diabetes.
The Committee concluded that people with type 2 diabetes currently receiving liraglutide who do not meet the criteria specified in section 1.1 or 1.3, or who are receiving liraglutide 1.8 mg, should have the option to continue their current treatment until they and their clinicians consider it appropriate to stop.

According to this study, over the next five years the Liraglutide market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2024, from US$ xx million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Liraglutide business, shared in Chapter 3.

This report presents a comprehensive overview, market shares, and growth opportunities of Liraglutide market by product type, application, key manufacturers and key regions and countries.

This study considers the Liraglutide value and volume generated from the sales of the following segments:

Segmentation by product type: breakdown data from 2014 to 2019, in Section 2.3; and forecast to 2024 in section 11.7.
Pills
Liquid
Segmentation by application: breakdown data from 2014 to 2019, in Section 2.4; and forecast to 2024 in section 11.8.
Hospital
Drug Store

This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Spain
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
HEC Pharm
Bachem
Bharat Pharmaceuticals
Kingpep Biotechnology
Shenzhen JYMed Technology
Wuxi Asiapeptide
AmbioPharm
...

In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.

Research objectives
To study and analyze the global Liraglutide consumption (value & volume) by key regions/countries, product type and application, history data from 2014 to 2018, and forecast to 2024.
To understand the structure of Liraglutide market by identifying its various subsegments.
Focuses on the key global Liraglutide manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Liraglutide with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the consumption of Liraglutide submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.